{"id":"05240","slug":"enhanced-immunogenic-murine--05240","source":{"id":"05240","dataset":"techtransfer","title":"Enhanced Immunogenic Murine Tumor Cell Lines","description_":"<p>This invention comprises novel murine tumor cell lines genetically engineered to express an active form of the cytokine interleukin-33 (IL-33). By modifying these cells, the technology significantly enhances the body&#39;s natural antitumor immune response.</p><p><h2>Description</h2>The technology utilizes advanced genetic engineering to introduce an active version of mouse IL-33 into established tumor cell lines, specifically 4T1 and B16F0. By expressing this potent cytokine, the otherwise non-immunogenic tumor cells are transformed into immunogenic targets that actively recruit and activate the immune system.\r\n\r\nThis approach modifies the tumor microenvironment to promote a robust anti-tumor response mediated by CD8+ T cells and Natural Killer (NK) cells. By effectively \"marking\" the tumor cells, this method provides a superior model for studying immune-mediated tumor suppression and developing potential immunotherapeutic strategies.</p><p><h2>Applications</h2>- Cancer Immunotherapy Development: Used by pharmaceutical companies to screen and validate novel immunotherapy drugs.\r<br>- Drug Discovery Research: Serves as a robust model for preclinical testing of combination therapies.\r<br>- Academic and Clinical Research: Facilitates high-level investigation into the mechanics of the tumor microenvironment.\r<br>- Biotechnology Assay Development: Utilized for developing high-throughput assays to measure immune response against specific tumor types.</p><p><h2>Advantages</h2>- Enhanced Immunogenicity: Effectively transforms standard tumor cell lines into highly immunogenic targets.\r<br>- Targeted Immune Activation: Specifically modifies the tumor microenvironment to trigger a more aggressive immune response.\r<br>- In-Vivo Efficacy: Demonstrated ability to inhibit tumor growth through the recruitment of CD8+ T cells and NK cells.\r<br>- Research Superiority: Provides a more accurate and responsive model for cancer immunotherapy studies compared to unmodified cell lines.\r<br>- Novel Therapeutic Platform: Serves as a foundational tool for investigating cytokine-based cancer interventions.</p><p><h2>Invention Readiness</h2>The technology has advanced through the initial development phase, with successful validation provided by in vivo studies. Data indicates that these modified cell lines are capable of inhibiting tumor growth by significantly altering the surrounding immune landscape. Further studies are required to fully optimize these cell lines for broader clinical application and industrial-scale use.</p><p><h2>IP Status</h2>Research Tool</p><p></p>","tags":["Genetics","Immuno-oncology"],"file_number":"05240","collections":[],"meta_description":"Genetically engineered murine tumor lines expressing active IL-33 boost immunogenicity, recruiting CD8+ T cells and NK cells to suppress tumors.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":2.0},\"weighted_score\":3.6,\"risks\":[\"Potential novelty overlap with existing IL-33 tumor modulation work\",\"IP status is Research Tool; limited exclusivity\",\"Readiness may require regulatory/commercial validation for clinical use\",\"Scalability may depend on cell line maintenance and transferability to other models\",\"Timeline to clinical translation uncertain; aging data (2020) may affect relevance)\"],\"one_sentence_take\":\"High novelty and impact as a robust immunogenic tumor model with strong research utility, but readiness and market exclusivity limit near-term commercialization; timeliness somewhat hindered by older reference date.\"}","lead_inventor_name":"Binfeng Lu","lead_inventor_dept":"Med-Immunology","technology_type":"Life Science Research Tool","technology_subtype":"Cell Line","therapeutic_areas":["Oncology"],"therapeutic_indications":["Solid tumor"],"custom_tags":[],"all_tech_innovators":["Xin Gao","Gang Li","Binfeng Lu"],"date_submitted":"2020-02-06","technology_readiness_level":"4. Prototype testing and refinement"},"highlight":{},"matched_queries":null,"score":0.0}